MPS IIIA Gene Therapy, ABO-102, Shows Efficacy in Trial Update – Rare Disease Report
Voice Of Analysts |
MPS IIIA Gene Therapy, ABO-102, Shows Efficacy in Trial Update
Rare Disease Report This morning, Abeona Therapeutics Inc. released positive data from its phase 1/2 trial for ABO-102 (AAV-SGSH), a clinical gene therapy for the treatment of Sanfilippo syndrome type A (MPS III A). The data were presented at the 21st Annual Meeting of … Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting Abeona Therapeutics (ABEO) Announces Clinical Update on MPS IIIA Gene Therapy Trial Abeo down 12% on gene therapy data in Sanfilippo |
